Financial Data and Key Metrics Changes - In Q4 2025, IFF generated revenue of nearly $2.6 billion, with a 1% growth compared to a 6% year-ago comparable, and a 4% increase on a two-year average basis [12] - EBITDA totaled $437 million for Q4, a 7% increase, with EBITDA margin increasing by 90 basis points to 16.9% [12] - For the full year 2025, IFF achieved 7% EBITDA growth with 100 basis points of margin expansion [11] Business Line Data and Key Metrics Changes - Taste segment sales increased 2% to $588 million, with EBITDA rising 17% to $94 million [13] - Health & Biosciences segment achieved sales of $589 million, a 5% increase, with EBITDA growing 20% to $155 million [15] - Scent segment delivered sales of $610 million, representing 4% growth, with EBITDA increasing 1% to $106 million [16] - Food Ingredients sales were down 4% to $802 million, but EBITDA grew by 10% due to margin improvements [14] Market Data and Key Metrics Changes - The performance in North America for the Taste segment showed high-single-digit growth driven by new wins [13] - Health & Biosciences saw strong growth in Food Biosciences and Animal Nutrition, both growing double digits [15] - The Scent segment's Fine Fragrance grew by 10%, while Fragrance Ingredients faced pressure due to market softness [16] Company Strategy and Development Direction - IFF is focusing on high-value, innovation-driven businesses, having completed divestitures of several lower-margin businesses [8] - The company is pursuing a sale for its Food Ingredients business to optimize its portfolio [9] - IFF aims to drive profitable growth while maintaining a disciplined capital allocation strategy, with net debt to credit-adjusted EBITDA down to 2.6x [7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, expecting sales growth in the range of $10.5 billion to $10.8 billion, representing 1%-4% growth [20] - The company anticipates that macroeconomic uncertainty will persist but believes in its ability to achieve consistent, profitable growth [10] - Management highlighted the importance of innovation and productivity in driving future performance [26] Other Important Information - Cash flow from operations totaled $850 million for the full year, with CapEx at $594 million [16] - The company returned $409 million to shareholders through dividends and share repurchases [18] - IFF's cash and cash equivalents finished at $590 million, with gross debt decreasing by nearly $3 billion compared to 2024 [18] Q&A Session Summary Question: Assumptions around price and volume in 2026 - Management indicated that expected growth for 2026 is volume-driven, with incremental margins on volumes around 30%-35% depending on the business segment [32] Question: Top and bottom end of the 1%-4% currency neutral sales outlook - Management expressed cautious optimism, driven by a strong pipeline and customer emphasis on volume growth, with expectations for all divisions to grow within the range [35] Question: Early interest in the sale of Food Ingredients - Management confirmed strong interest from both strategic and private equity firms, with proceeds expected to be used for share buybacks and debt reduction [40] Question: Price dynamics in the Scent segment - Management noted that pricing was flat year-over-year, with margin pressure primarily from input costs, and a shift towards higher growth proprietary ingredients will take time [42] Question: Health & Biosciences margin uplift - Management attributed strong performance to volume growth and productivity, with expectations for the Health business to stabilize and grow in the second half of 2026 [46] Question: Free Cash Flow expectations - Management expects meaningful improvement in Free Cash Flow for 2026, driven by profitability growth and disciplined cash management [51] Question: R&D efforts and innovation pipeline - Management reported significant investments in innovation capabilities, with expected benefits starting in the second half of 2026 [56] Question: Reformulation opportunities in the marketplace - Management noted ongoing reformulation trends, with opportunities for IFF to support customers in creating healthier products [85]

Financial Data and Key Metrics Changes - In Q4 2025, IFF generated revenue of nearly $2.6 billion, with a 1% growth compared to a 6% year-ago comparable, and a 4% increase on a two-year average basis [12][10] - EBITDA totaled $437 million for Q4, a 7% increase, with an EBITDA margin increase of 90 basis points to 16.9% [12][10] - For the full year 2025, IFF achieved 7% EBITDA growth with 100 basis points of margin expansion [11] Business Line Data and Key Metrics Changes - Taste segment sales increased 2% to $588 million, with EBITDA up 17% to $94 million [13] - Health and Biosciences segment sales grew 5% to $589 million, with EBITDA increasing 20% to $155 million [15] - Scent segment sales rose 4% to $610 million, with EBITDA increasing 1% to $106 million [16] - Food ingredients sales decreased 4% to $802 million, but EBITDA grew 10% with a 150 basis points margin expansion [11][15] Market Data and Key Metrics Changes - The performance in North America for the Taste segment showed high single-digit growth driven by new wins [13] - Health and Biosciences saw strong growth in food biosciences and animal nutrition, both achieving double-digit growth [15] - The Scent segment's fine fragrance experienced double-digit growth, while fragrance ingredients faced declines due to market softness [11][16] Company Strategy and Development Direction - IFF is focusing on high-value, innovation-driven businesses, having divested from lower-margin segments [8][9] - The company is pursuing a sale for its food ingredients business to optimize its portfolio [8][19] - IFF aims to enhance competitiveness through investments in innovation, digital transformation, and operational excellence [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, expecting sales growth in the range of $10.5 billion to $10.8 billion, representing 1%-4% growth [20] - The company anticipates EBITDA for 2026 to be between $2.05 billion and $2.15 billion, reflecting 3%-8% growth [21] - Management acknowledged ongoing macroeconomic uncertainties but emphasized confidence in achieving profitable growth [10][20] Other Important Information - Cash flow from operations totaled $850 million for the full year, with CapEx at $594 million [16] - The company returned $409 million to shareholders through dividends and share repurchases [17] - IFF's net debt to credit-adjusted EBITDA improved to 2.6 times, down from 3.8 times in 2024 [18] Q&A Session Summary Question: Assumptions around price and volume in 2026 - Management indicated that expected growth for 2026 is volume-driven, with incremental margins on volumes around 30%-35% depending on the segment [30][31] Question: Top and bottom end of the 1%-4% currency neutral sales outlook - Management expressed cautious optimism, driven by a strong pipeline and customer emphasis on volume growth [33][34] Question: Early interest in the sale of food ingredients - Management confirmed strong interest from both strategic and private equity firms, with proceeds expected to be used for share buybacks and debt reduction [39][41] Question: Price dynamics in the scent segment - Management noted that pricing was flat year-over-year, with margin pressure primarily from input costs [43][44] Question: Health and biosciences margin uplift - Management attributed strong performance to volume growth and productivity, with expectations for stabilization and growth in the health business [46][48] Question: Free cash flow expectations for 2026 - Management expects meaningful improvement in cash flow driven by profitability growth and working capital management [50][52] Question: R&D efforts and innovation metrics - Management highlighted a $100 million investment in innovation capabilities, with expected benefits materializing in the second half of 2026 [56][58] Question: Reformulation opportunities in the marketplace - Management noted ongoing reformulation trends, viewing them as opportunities for growth in healthier product offerings [88][90]

Financial Data and Key Metrics Changes - In Q4 2025, IFF generated revenue of nearly $2.6 billion, with a 1% growth compared to a 6% year-ago comparable, and a 4% increase on a two-year average basis [11] - EBITDA totaled $437 million for Q4, a 7% increase, with an EBITDA margin increase of 90 basis points to 16.9% [11] - For the full year 2025, IFF achieved 7% EBITDA growth with 100 basis points of margin expansion [10] Business Segment Performance Changes - Taste segment sales increased 2% to $588 million, with EBITDA up 17% to $94 million [12] - Health and Biosciences segment sales grew 5% to $589 million, with EBITDA increasing 20% to $155 million [13] - Scent segment delivered sales of $610 million, representing 4% growth, with EBITDA increasing 1% to $106 million [14] - Food ingredients sales were down 4% to $802 million, but EBITDA grew by 10% due to margin improvements [12][14] Market Data and Key Metrics Changes - The performance in North America for the Taste segment showed high single-digit growth, driven by new wins [12] - Health and Biosciences saw strong growth in food biosciences and animal nutrition, both achieving double-digit growth [13] - The Scent segment's fine fragrance grew by 10%, while fragrance ingredients faced pressure due to market softness [14] Company Strategy and Development Direction - IFF is focusing on high-value, innovation-driven businesses, having divested from lower-margin segments [6][8] - The company is optimistic about the sale process for its food ingredients business, aiming to enhance shareholder value [17] - Investments in R&D, commercial capabilities, and manufacturing capacity are prioritized to drive profitable growth [5][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving consistent, profitable growth despite macroeconomic uncertainties [9] - For 2026, IFF expects sales in the range of $10.5 billion to $10.8 billion, representing 1%-4% growth [18] - EBITDA for 2026 is projected to be between $2.05 billion and $2.15 billion, indicating 3%-8% growth [19] Other Important Information - Cash flow from operations totaled $850 million for the full year, with CapEx at approximately 5.5% of sales [14] - The company returned $409 million to shareholders through dividends and share repurchases [15] - The net debt to credit-adjusted EBITDA ratio improved to 2.6 times, down from 3.8 times in 2024 [16] Q&A Session Summary Question: Assumptions around price and volume in 2026 - Management indicated that growth for 2026 is expected to be volume-driven, with incremental margins on volumes around 30%-35% depending on the segment [28][29] Question: Top and bottom end of the 1%-4% currency neutral sales outlook - Management expressed cautious optimism, driven by a strong pipeline and customer focus on volume growth, with expectations for all divisions to grow within the range [31][32] Question: Early interest in the sale of food ingredients - Management confirmed strong interest from both strategic and private equity firms, with optimism about the sale process [36][37] Question: Price dynamics in the scent segment - Management noted that pricing was flat year-over-year, with margin pressure primarily from input costs, and a gradual shift towards higher-value ingredients is expected [40][41] Question: Health and biosciences margin uplift - Strong volume growth and productivity improvements contributed to the margin uplift, with expectations for stabilization and growth in the health business [43][44] Question: Free cash flow expectations for 2026 - Management anticipates meaningful improvement in free cash flow driven by profitability growth and working capital management [46][49] Question: R&D efforts and innovation metrics - Management highlighted a $100 million investment in innovation capabilities, with expected benefits starting in the second half of 2026 [53][56] Question: Reformulation opportunities in the marketplace - Management noted ongoing reformulation trends, with opportunities for IFF to support customers in creating healthier products [82][84]